-
Focusing on the progress of diagnosis and treatment of neuroblastoma, focusing on the landing of targeted immunotherapy-"Neuroblastoma Targeted Immunity Frontier Forum" conference report
Time of Update: 2022-01-09
Professor Xiaowen Zhai of the Children's Hospital of Fudan University stated in his opening speech that 2021 will be a special year for domestic high-risk patients with goddesses, because two GD2 targeted immunotherapy drugs have been introduced into China .
-
Reduce CD3 affinity-the application of CD3 double antibodies in the treatment of solid tumors
Time of Update: 2022-01-09
The in vivo efficacy and cytokine release of MUC16-CD3 double antibodies with different affinities in a mouse tumor model The tissue distribution of Amgen’s AMG757 CD3 double antibody for solid tumor treatment is mainly based on the HLE BiTE platform.
-
Real-world study results of Venecla in the treatment of patients with relapsed and refractory multiple myeloma
Time of Update: 2022-01-09
In t(11;14) patients, the median OS of patients with and without high-risk cytogenetic abnormalities was 13 months and not reached (P<0.
Among patients without t(11;14), the median OS of patients with and without high-risk cytogenetics was 10 months and not reached (P=0.
-
Prof. Zhiyong Ma: The first-line indications and comprehensive coverage of medical insurance for the advanced NSCLC of Bazaar® help NSCLC enter the "chronic disease era"
Time of Update: 2022-01-09
On January 1, 2022, China's independent innovation of PD-1 monoclonal antibody-Bezian® (Tilelizumab) combined with chemotherapy was used for the first-line treatment of advanced squamous and non-squamous non-small cell lung cancer (NSCLC) The indications of the disease will enter the 2022 national medical insurance, and the disease burden of patients will be greatly reduced .
-
7 tables to master the NCCN guidelines for 2022 v1 NSCLC treatment options
Time of Update: 2022-01-09
*It is only for medical professionals to read the reference.
Recently, the National Cancer Network (NCCN) updated the 2022 v1 non-small cell lung cancer (NSCLS) diagnosis and treatment guidelines .
The guide is updated, one step ahead!
-
Chinese study: PI3K/AKT pathway activation is a potential mechanism of small cell lung cancer treatment resistance
Time of Update: 2022-01-09
Enrichment of genome changes after radiotherapy and chemotherapy In the PI3K/AKT pathway, the genome profiles of newly treated and recurring SCLC tumors are first compared to determine the genomes related to recurrence after CCRT .
-
Have you seen skin metastases in rare cases of bladder cancer?
Time of Update: 2022-01-09
The prognosis of patients with skin metastases of bladder cancer is poor .
Researchers believe that the most likely mechanism for skin metastasis in this patient is the lymphatic spread of tumor cells through the lymphatic fistula .
-
2021 NCCN and CSCO Breast Cancer Guidelines Update
Time of Update: 2022-01-09
Advanced rescue treatment points 8 Advanced triple-negative breast cancer first-line first-line first-line option is newly added "Pembrolizumab + chemotherapy (albumin combined with paclitaxel, paclitaxel, gemcitabine and carboplatin)", the patient is PD-L1 positive (CPS score> 10 points ) .
-
The whole course of neoadjuvant treatment for rectal cancer: the order of chemotherapy and radiochemotherapy
Time of Update: 2022-01-09
A previous multicenter, randomized phase 2 trial in Germany enrolled 306 patients with stage II or III rectal cancer who received a full course of neoadjuvant therapy (CAO/ARO/AIO-12; J Clin Oncol 2019; 37:3212).
-
A new end point for MM treatment?
Time of Update: 2022-01-09
The results of the study showed that compared with placebo, ixazomib can significantly improve the PFS of MRD+ patients at the time of enrollment (median PFS 18.
-
Targeting CD79b!
Time of Update: 2022-01-09
On December 21, 2021, CDE included Vibotuzumab in the proposed priority review for the treatment of adult patients with relapsed or refractory diffuse large B lymphoma (DLBCL) .
-
The latest progress of pembrolizumab combination in the treatment of classic Hodgkin's lymphoma ASH 2021
Time of Update: 2022-01-09
Abstract number: 229 Pembrolizumab combined with ICE chemotherapy produced a high complete metabolic remission rate for relapsed/refractory classic Hodgkin’s lymphoma (cHL): a multi-institution phase II trial with a research background of approximately 30 -35% of cHL patients will prove to be refractory to first-line treatment or later relapse .
-
Professor Jiang Zefei: Looking back and looking forward to comprehensively promoting a new model of breast cancer diagnosis and treatment in multiple fields and new situations
Time of Update: 2022-01-09
Gallen Breast Cancer Conference, the international expert group online meeting as scheduled, to promote the overall development of the breast cancer field Professor Jiang Zefei once a year The annual review meeting of breast cancer treatment progress is coming as scheduled.
-
Late mortality and life expectancy of Allo-HSCT recipients in the past 40 years
Time of Update: 2022-01-09
Based on this, some researchers have carried out a blood or bone marrow transplant survivor study (BMTSS) to analyze the cumulative impact of long-term complications and early mortality of Allo-HSCT recipients on life expectancy .
-
High score review: reviewing the past and learning the new in immunotherapy for primary liver cancer
Time of Update: 2022-01-09
2. Anti-PD-1/PD-L1 and anti-CTLA-4 targeted drugs combined use CheckMate 040 cohort study to evaluate patients with advanced HCC treated with sorafenib, the application of anti-CTLA4 antibody Ipilimumab (Ipilimumab) and The safety and efficacy of Nivolumab combination therapy showed that the ORR was 32% and the median OS was 23 months .
-
IMmotion151 research final OS results released
Time of Update: 2022-01-09
The interim analysis of the IMmotion151 study showed that atilizumab + bevacizumab compared with sunitinib can significantly improve the progression-free survival (PFS) of patients, reaching the primary study endpoint .
-
The 2021 version of the guidelines for the clinical application of new anti-tumor drugs is released!
Time of Update: 2022-01-09
The "Guiding Principles" emphasize that the clinical application of anti-tumor drugs must follow the drug instructions and cannot be used beyond the indications at will .
-
Breaking the siege, Yang Sen BCMA/CD3 dual antibody submitted a listing application to the FDA, Medical Mai Meng broke the news
Time of Update: 2022-01-09
The drug targets B cell maturation antigen (BCMA) and CD3, and is being developed for the treatment of relapsed or refractory (r/r) multiple myeloma .
Teclistamab is a bispecific antibody developed using Genmab DuoBody® technology that can simultaneously target T cell CD3 and multiple myeloma (MM) cell BCMA .
-
Explore the headline sword refers to the "king of cancer"!
Time of Update: 2022-01-09
Recently, the team of Professor Yin Yuxin of Peking University School of Basic Medicine and collaborators of the Chinese Academy of Sciences and the Chinese People’s Liberation Army General Hospital applied machine learning combined with lipidomics and multi-omics techniques to comprehensively analyze the metabolic characteristics of pancreatic ductal adenocarcinoma (pancreatic cancer), and developed an artificial The intelligent-assisted PDAC serum metabolism detection method achieved 86.
-
Big coffee explores the "Australia" expert connection, talks about the new progress, new changes, and new cornerstones of inert NHL treatment
Time of Update: 2022-01-09
According to Professor Huang Haiwen, in almost all clinical trials of indolent NHL, a combined treatment plan of Otuzumab and related therapeutic drugs will be used, and major domestic and foreign guidelines have gradually included Otuzumab as the treatment recommendation for FL With the advancement of medical insurance policies, more and more patients benefit from otuzumab .